DUE FROM SUBSIDIARIES Continued 2012 2011 Current assets $000 $000 Due from Hikma Pharma Limited Jersey 7,491 7,222 Due from Hikma Farmaceutica Portugal 643 487 Due from Hikma Pharma Germany 113 78 Due from Hikma UK Limited 90,291 93,446 Due from Hikma Limited 625 580 Due from Hikma MENA Holdings Limited 14,229 7,151 Due from West-Ward Pharmaceutical Corp. 837 1,196 Due from Hikma Pharmaceuticals Limited Jordan 20,109 Others 1,991 1,506 136,329 111,666 45.
FINANCIAL ASSETS Cash and cash equivalents These comprise cash held by the Company and short-term bank deposits with an original maturity of three months or less.
The carrying amount of these assets approximates to their fair value.
FINANCIAL LIABILITIES Other payables The Directors consider that the carrying amount of other payables approximates to their fair value.
DUE TO SUBSIDIARIES 2012 2011 $000 $000 Due to Hikma Holdings 591,800 Due to Hikma Pharmaceuticals Limited Jordan 200 Due to Hikma Phamia Limited Jersey 15 Due to Hikma Investment Ltd. 728 Due to Eurohealth NV 15,474 16,217 592,000 These balances mainly represent amounts due to Hikma Holdings UK Ltd which are non-interest-bearing loans repayable on demand.
During the year ended 31 December 2012, Hikma undertook an internal reorganisation of the Group subsidiary structure.
The ultimate interest inall subsidiaries remains unchanged.
As a result of this re-organisation, the non-interest bearing loan with Hikma Holdings UK Limited ceased.
LONG-TERM FINANCIAL DEBTS The Company has a seven-year syndicated term loan of $180,000,000 which was entered into on 27 September 2011.
The loan has an outstanding balance at year end of $172,468,000 with a fair value of $170,541,000 from which $21,705,000 is due in one year and a zero unused available limit.
Quarterly repayments for the term loan should commence 18 months after the date of the agreement and will continue until the 84th month after the date of the agreement.
Payment will be made with equal instalments representing 3.182% of the loan balance and a bullet payment of 30% at the maturity of the loan.
The loan was used to finance the Promopharm acquisition and the Groups general capital expenditure.
HIKMA PHARMACEUTICALS PLC ANNUAL REPORT 2012 161
